Skip to content
☰ Menu
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

Authors not listed

Pfizer · 2009

Dysbiosis Human Randomized controlled trial
＋ Sign in to save

Abstract

This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day. The results of this study will help inform and guide further formulation development efforts with the ultimate goal of reducing dose frequency to once-a-day or twice-a-day.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-26 MST

Cite this

APA
Anonymous. (2009). A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine). <em>Pfizer</em>. https://clinicaltrials.gov/study/NCT00988624
Vancouver
Anonymous. A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine). Pfizer. 2009.
BibTeX
@misc{anon2009APhase, title = {A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)}, author = {Anonymous}, journal = {Pfizer}, year = {2009}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings